Insulin aspart is a rapid-acting, human insulin analog that is FDA approved to treat type-1 and type-2 diabetes mellitus to improve glycemic control in adults and children. Insulin aspart may also be used to treat diabetic ketoacidosis (DKA), though this is not an FDA-approved indication. This activity outlines the indications, mechanism of action, safe administration, adverse effects, contraindications, monitoring, and toxicity of insulin aspart.

**Objectives:**
- Identify the appropriate indications for insulin aspart.
- Summarize the appropriate dosing of insulin aspart as part of a glycemic control regimen.
- Describe the potential adverse event profile and contraindications of insulin aspart.
- Outline interprofessional team strategies for improving care coordination and communication to advance appropriate clinical outcomes with insulin aspart therapy as part of a diabetes mellitus glycemic control treatment plan leading to optimal patient outcomes.